Respiratory failure & ventilation
The safety and efficacy of mesenchymal stromal cells in acute respiratory distress syndrome (ARDS): a meta-analysis of randomized controlled trials
Pooled result · MortalityResult — go to the resultOdds ratio 0.66 95% CI 0.46–0.96Authors' conclusion
Based on the results of our meta-analysis, the safety of MSC was demonstrated to be non-inferior to that of standard treatment, and MSC may reduce the mortality rate of ARDS.
Study context
- Population
- Patients with ARDS (including COVID-19-induced ARDS)
- Participants
- 655 patients · 13 randomized controlled trials (RCTs)
- Comparison
- Intravenous mesenchymal stromal cells (MSC) vs control
- Outcome
- Mortality
Methodological detailsfixed- or random-effect model by I2
- Fixed- or random-effect model by I2
Pooled result
As reported in the abstract
Odds ratio
0.66
95% CI 0.46–0.96
P = 0.03
MSC vs Control
OR 0.66 (95% CI 0.46–0.96); P = 0.03
Safety
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| Adverse eventsI2 = 0% · no significant difference | 0.64 (0.34–1.20) | P = 0.17 | |
| 0.20.5125Odds ratio (log scale) |
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
The safety and efficacy of mesenchymal stromal cells in ARDS: a meta-analysis of randomized controlled trials. Crit Care. Published 20 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →